Sign In

QOPI
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma

Oncology Practice Insider

Related

FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection in Patients with Hematologic Malignancies
FDA Approves Dabrafenib With Trametinib For Pediatric Patients With Low-grade Glioma With a BRAF V600E Mutation
FDA Expands Early Breast Cancer Indication For Abemaciclib With Endocrine Therapy
FDA Alerts

On September 14, 2021, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. Read more.